Coverage changes for Stelara and biosimilars

We want to make you aware of upcoming coverage changes related to Stelara (ustekinumab) and biosimilars. Effective July 1, 2025 for CarePartners of Connecticut members, the ustekinumab biosimilars Yesintek (ustekinumab-kfce) and Steqeyma are being added to the part D formulary and Stelara is being removed. We have notified affected members of these changes, as well. 

To continue providing ustekinumab therapy, prescribers should utilize Yestinek and Steqeyma, which will be more cost effective for your patients than Stelara.

Prior authorization is required for these medications. However, the existing authorization for Stelara will be valid for Yesintek and Steqeyma, and you do not need to submit a new prior authorization request until that prior authorization expires.

We strongly recommend that you write a new prescription for Yesintek or Steqeyma to make the transition as seamless as possible.